MALVERN, Pa. — Drug developer Novavax Inc. on Tuesday said the Centers for Disease Control and Prevention agreed to test the company's bird flu vaccine against a live strain of the H5N1 virus that causes the disease.
Under the agreement, Novavax will provide the CDC with a year's supply of its virus-like particle, or VLP, H5N1 vaccine. Novavax also plans to begin human testing of the vaccine in the first half of 2007.
VLPs are structures that are identical to a virus but lack the genetic material required to replicate, allowing for the body to produce an immune response without risking an infection.
Novavax shares rose 47 cents, or 11.5 percent, to $4.57 in premarket electronic trading, after closing at $4.10 Monday on the Nasdaq.